ESR1 and breast carcinoma: Since high expression of CCNA2 confers poor DMFS, DFS, RFS and OS in ER+ breast cancer patients and tamoxifen is one of the most widely used drugs for the management of those ER+ patients, CCNA2 may play a potential role in tamoxifen resistance.